Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Prospective Evaluation of MyocaRdial PerFUSion ComputEd Tomography Trial

NCT02208388 · tracked via the Priya Life Science South Korea tracker
Sponsor
Young-Hak Kim, MD, PhD
Phase
Not applicable
Started
2014-08-12
Last updated
2023-04-05

Condition(s) studied

Coronary Disease

Investigational drug(s) / intervention(s)

computed tomography perfusion guided treatmentFractional flow reserve guided treatment

Study summary

The purpose of this study is to evaluate safety and effectiveness of CTP(computed tomography perfusion) guided revascularization vs FFR(Fractional flow reserve) guided revascularization

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age 20 and more * Diagnosed angina or angina equivalent symptom or positive exercise treadmill test * Patients with intermediate- or high-risk probability of CAD defined by Diamond and Forester * 70 % stenosis or more in coronary CTA * Willing to provide informed, written consent Exclusion Criteria: * Requirement for surgical procedure * Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support * Recent STEMI (\<5 days) * Non STEMI, if the cardiac troponin is not stable or starting to decline * Left ventricular ejection fraction \<30% * Life expectancy \<2 years * Impaired renal function with an effective glomerular filtration rate less than 30mL/min/1.73 ㎡ or creatinine more than 2.0 mg/dL * Undergoing evaluation for organ transplantation * Participation or planned participation in another cardiovascular clinical trial * Pregnancy * Inability to take dual antiplatelet therapy for six months * Previous CABG * Left main disease requiring revascularization * Any target lesion with in-stent restenosis * NYHA class 3 or 4a * Severe and persistent angina with severe limitation in everyday living activities (Canadian Cardiovascular Society grading Class IV)

Primary outcome measure(s)

  • Composite Events — 1 year
    All cause death, Myocardial infarction, Diseased-related unplanned hospitalization or stroke

Trial sites (7)

FacilityCityRegionStatus
Asan Medical Center Seoul Songpa-Gu Recruiting
Hallym University Sacred Heart Hospital Anyang South Korea Completed
Gangwon National Univ. Hospital Chuncheon South Korea Completed
Keimyung University Dongsan Medical Center Daegu South Korea Completed
Pusan National University Hospital Pusan South Korea Enrolling By Invitation
Pusan National University Yangsan Hospital Pusan South Korea Completed
Severance Hospital Seoul South Korea Withdrawn
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02208388 on ClinicalTrials.gov ↗ ← All trials in South Korea